DRUG
Cyclophosphamide
Cyclophosphamide is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Epirubicin.
Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
Status
Recruiting
Phase
Phase 2
Enrollment
85
Locations
4
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The primary purpose of this study is to determine what proportion of participants will achieve complete pathological response with epirubicin+ cyclophosphamide followed by docetaxel +carboplatin. This will also examine the potential of using signals in the blood (biomarkers) to identify resistance to chemotherapy in Nigerian women with triple negative breast cancer (TNBC). All enrollment to this trial will occur at sites in Nigeria. University of Chicago is serving as coordinating center and will be involved in data analysis.
Interventions
Treatment arms and agents.
DRUG
Epirubicin
Epirubicin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Cyclophosphamide.
DRUG
Docetaxel
Docetaxel is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Carboplatin. Dosing will start after treatment with Epirubicin and Cyclophosphamide (EC) is completed.
DRUG
Carboplatin
Carboplatin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Docetaxel. Dosing will start after treatment with EC is completed.
PROCEDURE
Breast Surgery
Participants will undergo breast surgery after completing dosing with Carboplatin and Docetaxel to remove any remaining cancer in the breast.
DRUG
Capecitabine
Capecitabine is a pill that will be taken by mouth daily for 6 months after surgery is completed.
Timeline
From registration to results.
First posted
Mar 4, 2024
Study start
Mar 18, 2025
Primary completion
Jun 2029
Study completion
Jun 2032
Results posted
Not reported
Registry updated
Feb 17, 2026
Outcomes
What the study measures.
Primary outcomes
Percentage of Participants that Achieve Pathologic Complete Response (pCR) Rate (Breast)
Time frame · 4 - 6 months from start of chemotherapy
How well does the study chemotherapy regimen of epirubicin and cyclophosphamide (EC) followed by docetaxel and carboplatin work to remove tumor cells in the breast. This will be determined by percentage of participants that do not have noticeable cancer cells in the breast after completing the chemotherapy regimen.
Percentage of Participants that Achieve Pathologic Complete Response (pCR) Rate (Lymph Nodes)
Time frame · 4 - 6 months from start of chemotherapy
How well does the study chemotherapy regimen of epirubicin and cyclophosphamide (EC) followed by docetaxel and carboplatin work to remove tumor cells in the lymph nodes. This will be determined by percentage of participants that do not have noticeable cancer cells in the lymph nodes after completing the chemotherapy regimen.
Percentage of Participants that Achieve Pathologic Complete Response (pCR) Rate (By Stage)
Time frame · 4 - 6 months from start of chemotherapy
How well does the study chemotherapy regimen of epirubicin and cyclophosphamide (EC) followed by docetaxel and carboplatin work to remove tumor cells based on stage of breast cancer. This will be determined by percentage of participants that do not have noticeable cancer cells in the lymph nodes after completing the chemotherapy regimen.
Secondary outcomes
Side Effects of the Study Pre-surgery Chemotherapy Regimen
Time frame · After 8 cycles of treatment (24 weeks)
Percentage of participants experiencing Grades 3 and 4 blood, gastrointestinal, neurological and cardiovascular toxicities.
Clinical Response
Time frame · 4 - 6 months from start of chemotherapy
Percentage of participants achieving clinical response (CR and PR) during neoadjuvant period by breast ultrasound
Progressive Disease
Time frame · After 8 cycles of treatment (24 weeks)
Percentage of participants with progressive disease during pre-surgery treatment period
Invasive Disease Free Survival (iDFS)
Time frame · 10 years from start of treatment
Time to cancer returning or death
Duration of Response
Time frame · 10 years from start of treatment
Time to cancer worsening or death
Heart Related Side Effects of the Pre-Surgery Chemotherapy Regimen
Time frame · 10 years from start of treatment
Percentage of participants with Heart failure (NYHA Class III or IV or as confirmed by a cardiologist) and a decrease in left ventricular ejection fraction (LVEF) of at least 10 ejection fraction (EF) points from baseline and to below 50%.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Sex
- FEMALE
- Healthy volunteers
- No
Inclusion Criteria: 1. Women ages of 18 to 70 years old 2. Women who are able and willing to read understand and sign an informed consent document 3. Biopsy-accessible breast tumor of significant size for core needle biopsy/ultrasound measurable (≥ 2cm) 4. Patients with histologically confirmed carcinoma of the female breast with triple-negative status by immunohistochemistry (IHC). Patients who are low estrogen reception (ER) expression (\< 20%), progesterone receptor (PR) negative and human epidermal growth factor 2 (HER2) negative are eligible. 5. Clinical stages IIA -IIIC (AJCC 2009) 6. Chemotherapy-naïve patients (for this cancer) 7. Performance status: Eastern Cooperative Oncology Group (ECOG) performance status 0-1 8. Non-pregnant and not nursing. * Granulocyte greater than or equal to 1,500/microliter * Platelet count greater than or equal to 100,000/microliter * Absolute neutrophil count (ANC) greater than or equal to l500/microliter * Hemoglobin greater than or equal to 10g/deciliter * Bilirubin less than or equal 1.5 x upper limit of normal * aspartate aminotransferase (ALT or SGOT) and alanine transaminase (AST or SGPT) less than 2.5 x upper limit of normal 7\. Creatinine within institutional normal limits or glomerular filtration rate greater than or equal to 30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) equation 10. Baseline left ventricular ejection fraction of greater than or equal to 55% Exclusion Criteria: 1. Pregnant or lactating women. 2. Patients with distant metastasis (brain and/or visceral metastasis) 3. Serious, uncontrolled, concurrent infection(s). 4. Treatment for other carcinomas within the last 5 years, except non-melanoma skin cancer and treated cervical carcinoma in-situ (CCIS) 5. Participation in any investigational drug study within 4 weeks preceding the start of study treatment 6. Other serious uncontrolled medical conditions that the treating investigator feels might compromise study participation including but not limited to chronic or active infection, HIV-positive patient, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled diabetes mellitus, or psychiatric illness/social situations that would limit compliance with study requirements.
Study locations
4 registered sites.
Nigeria. Showing up to 24 locations stored in the fast local snapshot.
Lagos State University Teaching Hospital
Ikeja, Lagos, Nigeria
Lagos University Teaching Hospital
Yaba, Lagos, Nigeria
Obafemi Awolowo University Teaching Hospitals Complex
Ile-Ife, Osun State, Nigeria
University of Ibadan Hospital
Ibadan, Oyo State, Nigeria
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Goserelin.
NCT IDStudyPhase / statusEnrollmentUpdated
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
National Cancer Institute (NCI) · Anatomic Stage III Breast Cancer AJCC v8 · Anatomic Stage IV Breast Cancer AJCC v8
Phase 3
Active, not recruiting
608
2026-07
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
ECOG-ACRIN Cancer Research Group · Prostate Carcinoma
Phase 3
Active, not recruiting
27
2026-07
Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.
RenJi Hospital · Prostate Cancer · Prostate
Phase 2
Not yet recruiting
200
2026-07
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Washington University School of Medicine · Breast Cancer · Cancer of Breast
Phase 2
Recruiting
50
2026-07
Effect of a GnRH Analog on Hepatic Steatosis
Aristotle University Of Thessaloniki · Metabolic Dysfunction-Associated Steatotic Liver Disease · Nonalcoholic Fatty Liver
Phase 4
Active, not recruiting
62
2026-07
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Mayo Clinic · Recurrent Castration-Sensitive Prostate Carcinoma · Recurrent Prostate Cancer
Phase 2
Recruiting
532
2026-07
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Novartis · Early Breast Cancer
Phase 3
Recruiting
1,400
2026-07
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Eli Lilly · Breast Neoplasms
Phase 2
Recruiting
600
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.